Vaccination trial with the PBF-derived peptide in HLA-A2+ patients with osteosarcoma
Phase 1
Recruiting
- Conditions
- osteosarcoma
- Registration Number
- JPRN-UMIN000001632
- Lead Sponsor
- Dept Orthopaedic Surgery, Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria included (i) prior chemotherapy, steroid therapy, or other immunotherapy within the past 4 weeks, (ii) presence of severe organ failure or other cancers that might influence the prognosis, (iii) immunodeficiency or a history of splenectomy, (iv) severe cardiac insufficiency, acute infection, or hematopoietic failure, (v) pregnany or ongoing breast-feeding, (vi) unsuitability for the trial based on the clinical judgment of the doctors involved.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Toxicity, immunological response, anti-tumor effects
- Secondary Outcome Measures
Name Time Method